Hana Biosciences (NASDAQ: HNAB) announced that it has acquired exclusive rights to develop and commercialize Menadione, a preclinical product candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE